Anti-CTLA-4 Ab

Immunotherapy of Cancer: An Innovative Treatment Comes of Age

Volumn , Issue , 2016, Pages 263-282

  Tokudome, Takuto ^a  

^a Bristol Myers KK   (Japan)

Author keywords

Advanced melanoma; CTLA 4; Durability of response; Immune checkpoint inhibitor; Immune related adverse events (irAE); Ipilimumab; Long term survival benefit

Indexed keywords

EID: 85030153433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55031-0_18     Document Type: Chapter

References (71)

1. Bretscher P et al (1970) A theory of self-nonself discrimination. Science 169:1042-1049
2. Lenschow DJ et al (1996) CD28/B7 system of T-cell costimulation. Annu Rev Immunol 14:233-258
3. Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-3895
4. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
5. Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
6. Brunet JF, Denizot F, Luciani MF et al (1987) A new member of the immunoglobulin superfamily - CTLA-4. Nature 328:267-270
7. Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201-210
8. Kearney ER, Walunas TL, Karr RW et al (1995) Antigen-dependent clonal expansion of a trace population of antigenspecific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 155(3):1032-1036
9. Krummel MF et al (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459-465
10. Krummel MF et al (1996) Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8(4):519-523
11. Walunas TL et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5):405-413
12. Perez VL, Van Parijs L, Biuckians A et al (1997) Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411-417
13. Chambers CA et al (1997) Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7(6):885-895
14. Tivol EA et al (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541-547
15. Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238):985-988
16. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618
17. Yang YF, Zou JP, Mu J et al (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57(18):4036-4041
18. McGaha T, Murphy JW (2000) CTLA-4 down-regulates the protective anticryptococcal cellmediated immune response. Infect Immun 68(8):4624-4630
19. Gomes NA, Barreto-de-Souza V, Wilson ME et al (1998) Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. J Infect Dis 178(6):1847-1851
20. Riley JL, Schlienger K (2000) Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 191(11):1987-1997
21. + regulatory T cells abrogates their function in vivo. J Immunol 177(7):4376-4383
22. 3+ regulatory T cell function. Science 322:271-275
23. Selby et al (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T. cells. Cancer Immunol Res 1:32-42
24. Simpson et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695
25. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105:14987-14992
26. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339
27. Camacho LH, Antonia S, Sosman J et al (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075-1081
28. Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622
29. National comprehensive cancer network clinical practice guidelines in oncology melanoma, version 3.2014
30. Dummer R, Hauschild A, Guggenheim M et al (2012) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Supplement 7): vii86-vii91
31. Kwon ED et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 14:700-712
32. Lynch TJ et al (2046) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, doubleblind, multicenter phase II study. J Clin Oncol 30(17):2012
33. Reck M et al (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive disease small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75-83
34. Nokihara H Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer. Presented at: IASLC 15th world conference on lung cancer
35. Ipilimumab Investigator Brochure16.
36. Maio M, Bondarenko I, Robert C et al Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine on phase III study CA184-024. ESMO 2012, Abstract 1127
37. Eggermont AM et al (2014) Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO 2014, LBA9008
38. Saenger YM et al (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1
39. Wolchok JD et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420
40. Maio M et al (2013) Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. Oral presentation ESMO 2013, Abstract 3704
41. Schadendorf D, Hodi FS, Robert C et al (2013) Late breaking abstract: pooled analysis of longterm survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. ECCO Amsterdam, LBA24
42. Prieto PA et al (2012) CTLA-4 blockade with ipilimumab: long term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047
43. YERVOY(tm) (ipilimumab) immune-mediated adverse reaction management guide. Available at: https://www.hcp.yervoy.com/pages/index.aspx. Accessed 9 Oct 2014
44. Giuseppina DVS et al (2014) Onco Targets Ther 7:203-209
45. Weber JS et al (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691-2697
46. Ribas A, Hodi FS, Callahan M et al (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-1366
47. Wolchok JD et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicenter, phase II, dose-ranging study. Lancet Oncol 11:155-164
48. Puzanov I, Callahan MK, Linette GP et al (2014) 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol 32 (suppl 5S):abstr 2511
49. Kaufman HL, Kirkwood JM, Hodi FS et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588-598
50. Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133
51. Sznol M, Kluger HM, Callahan MK et al (2014) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO 4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 32(suppl 5S):abstr LBA9003
52. Hammers HJ, Plimack ER, Infante JR et al (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32(suppl 5S):abstr 4504
53. Hodi FS, Lee SJ, McDermott DF et al (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312 (17):1744-1753
54. Puzanov I, Milhem MM, Andtbacka RHI et al (2014) Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 32 (suppl 5S):abstr 9029
55. Dhodapkar MV, Sznol M, Zhao B et al (2014) Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 6:232ra51
56. Neyns B, Wilgenhof S, Corthals J et al (2014) Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 32(suppl 5S):abstr 3014
57. Gibney GT, Hamid O, Gangadhar TC et al (2014) Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 32 (suppl 5s):abstr 3010
58. Barker CA, Postow MA, Khan SA et al (2013) Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1:92-98
59. Barker CA et al (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986-997
60. Lutzky J, Wolchok J, Hamid O et al (2009) Association between immune-related adverse events and disease control or overall survival in patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27:abstr 9034
61. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681-6688
62. Berman DM et al (2009) Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients with advanced melanoma treated with ipilimumab. J Clin Oncol 27:15s
63. Postow MA, Chasalow SD, Yuan J et al (2013) Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J Clin Oncol 31(suppl):abstr 9052
64. Tang DN, Shen Y, Yuan J et al (2013) Increased frequency of ICOSt CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1:229-234
65. Yuan J et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108:16723-16728
66. Kitano S, Postow M, Yuan J et al (2012) Myeloid derived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg predicts for clinical benefit and improved overall survival in patients with metastatic melanoma. J Clin Oncol 30, (suppl; abstr 2518)
67. Yuan J, Zhou J, Dong Z et al (2014) Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2:127-132
68. Hamid O et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204
69. Ji RR et al (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019-1031
70. van Rooij N, van Buuren MM, Philips D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439-e442
71. Charen AS, Makarov V, Merghoub T et al (2014) The neoantigen landscape underlying clinical response to ipilimumab. J Clin Oncol 32(suppl 5S):abstr 3003